Zobrazeno 1 - 10
of 216
pro vyhledávání: '"Daniel J Cuthbertson"'
Autor:
Christopher Wong, Kevin Mohee, Rajiv Sankaranarayanan, Archana Rao, Daniel J Cuthbertson, Julie Bellieu, Hani Essa, Homeyra Douglas, Lauren Walker, Justine Hadcroft, Matthew Kahn, Nick Hartshorne-Evans, Chukwuemeka Oguguo, Janet Bliss, Asangaedem Akpan
Publikováno v:
Open Heart, Vol 9, Iss 2 (2022)
Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. This retrospective observational study (January 2020–June 2021) analysed the impact of monthly HF multispecialty multidisciplina
Externí odkaz:
https://doaj.org/article/7f7a8651989e4176a197e9036643aa25
Autor:
Christina M van der Feltz-Cornelis, Jennifer Sweetman, Gail Allsopp, Emily Attree, Michael G Crooks, Daniel J Cuthbertson, Denise Forshaw, Mark Gabbay, Angela Green, Melissa Heightman, Toby Hillman, Lyth Hishmeh, Kamlesh Khunti, Gregory Y H Lip, Paula Lorgelly, Hugh Montgomery, W David Strain, Emma Wall, Caroline Watkins, Nefyn Williams, Dan G Wootton, Amitava Banerjee, STIMULATE-ICP Consortium
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0277936 (2022)
IntroductionAs mortality rates from COVID-19 disease fall, the high prevalence of long-term sequelae (Long COVID) is becoming increasingly widespread, challenging healthcare systems globally. Traditional pathways of care for Long Term Conditions (LTC
Externí odkaz:
https://doaj.org/article/7ec208ce26fd419cacb1045aaf1957b6
Autor:
Emily Brown, Victoria S Sprung, Graham J Kemp, John PH Wilding, Malcolm Burgess, Daniel J Cuthbertson, A Margot Umpleby, Jason C G Halford, Andrej Stancak, Moon M Wilton, Joanne A Harrold, Elaine Howarth
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
Introduction The newer glucose-lowering therapies for type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the sodium-glucose co-transporter 2 inhibitors (SGLT2i), have additional clinical benefits beyond improving glyc
Externí odkaz:
https://doaj.org/article/e58426e12bf4422080cccd3ed1011943
Autor:
Mark Gabbay, Michael Brady, Malgorzata Wamil, Daniel J Cuthbertson, Emily Attree, Melissa Heightman, Lyth Hishmeh, Johann Alberts, Jude Oben, Dan Wootton, Michael Crooks
Publikováno v:
BMJ Open, Vol 11, Iss 3 (2021)
Objective To assess medium-term organ impairment in symptomatic individuals following recovery from acute SARS-CoV-2 infection.Design Baseline findings from a prospective, observational cohort study.Setting Community-based individuals from two UK cen
Externí odkaz:
https://doaj.org/article/b585bd7544fc47ff9d03a17597dfc34a
Autor:
Victoria S Sprung, Graham J Kemp, John PH Wilding, Valerie Adams, Kieran Murphy, Malcolm Burgess, Stephen Emegbo, Matthew Thomas, Alexander J Needham, Andrew Weimken, Richard J Schwab, Ari Manuel, Sonya E Craig, Daniel J Cuthbertson
Publikováno v:
BMJ Open, Vol 10, Iss 7 (2020)
Introduction Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) often occur concurrently, and untreated OSA may potentially amplify the high risk of cardiovascular disease in T2DM. Compliance with continuous positive airway pressure (
Externí odkaz:
https://doaj.org/article/81600400deda44a58b7e80246290a587
Autor:
Matthew Anson, Alex E. Henney, Nicholas Broadwell, Sizheng S. Zhao, Gema H. Ibarburu, Gregory Y.H. Lip, John P.H. Wilding, Daniel J. Cuthbertson, Uazman Alam
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102777- (2024)
Summary: Background: Tirzepatide, a novel dual agonist of glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), has demonstrated greater magnitude of weight loss compared to semaglutide in a phase 3 clinical trial. H
Externí odkaz:
https://doaj.org/article/93b14b0a5d844a77bc3a8c1845bb3ae3
Autor:
Rebecca Dobson, Malcolm I Burgess, Melissa Banks, D Mark Pritchard, Jiten Vora, Juan W Valle, Christopher Wong, Carrie Chadwick, Keith George, Brian Keevil, Joanne Adaway, Joy E S Ardill, Alan Anthoney, Uschi Hofmann, Graeme J Poston, Daniel J Cuthbertson
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e73679 (2013)
PurposeMetastatic neuroendocrine tumors secrete serotonin and other vasoactive substances that are responsible for carcinoid syndrome and carcinoid heart disease. We sought to evaluate the discriminatory utility of diagnostic biomarkers in determinin
Externí odkaz:
https://doaj.org/article/5217811fa4b24bbab6c22b18b2408990
Autor:
Antonio J Ruiz-Alcaraz, Christopher Lipina, John R Petrie, Michael J Murphy, Andrew D Morris, Calum Sutherland, Daniel J Cuthbertson
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56928 (2013)
Insulin resistance (IR), an impaired cellular, tissue and whole body response to insulin, is a major pathophysiological defect of type 2 diabetes mellitus. Although IR is closely associated with obesity, the identity of the molecular defect(s) underl
Externí odkaz:
https://doaj.org/article/dbbdf793106c47e1a744e9a25b32b590
Autor:
Jing Kai Chang, Guoshou Teo, Yael Pewzner-Jung, Daniel J. Cuthbertson, Anthony H. Futerman, Markus R. Wenk, Hyungwon Choi, Federico Torta
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Untargeted lipidomics has been increasingly adopted for hypothesis generation in a biological context or discovery of disease biomarkers. Most of the current liquid chromatography mass spectrometry (LC–MS) based untargeted methodologies ut
Externí odkaz:
https://doaj.org/article/262b238c44154324aadaef3ea4909ce1
Autor:
Daniel J Cuthbertson, Andrew Irwin, Chris J Gardner, Christina Daousi, Tej Purewal, Niall Furlong, Niru Goenka, E Louise Thomas, Valerie L Adams, Sudeep P Pushpakom, Munir Pirmohamed, Graham J Kemp
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50117 (2012)
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver diseas
Externí odkaz:
https://doaj.org/article/e01c70efda824a5e8bbc489565553af5